Amphastar Pharmaceuticals, Inc. (AMPH): Net Income
$98.09M
Year ended 2025-12-31
$78.55M
Trailing 12 months to 2026-06-30
+2.4%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $98.09M | -38.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $159.52M | +16.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $137.54M | +50.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $91.39M | +47.1% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $62.12M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $1.40M | -97.1% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $48.94M | n/m | 2022-03-11, From 2019-01-01 |
| 2018-12-31 | -$5.74M | n/m | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | $3.65M | -62.9% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $9.82M | n/c | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | -$2.79M | n/m | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | -$10.70M | n/m | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $11.86M | -34.4% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $18.09M | n/a | 2015-03-26, From 2012-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $98.09M | -38.5% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | -$38.55M | n/m |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $7.03M | n/m |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $52.60M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $99.65M | -29.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $59.01M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$575.00M | n/m |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $62.87M | -9.1% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$183.17M | n/m |
Compare AMPH, SUPN, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗